Loading...
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
O'Brien, M E R Konopa, K Bosquee, L Marshall, E Bustin, F Margerit, S Fink, C Stigt, J A Dingemans, A
O'Brien, M E R
Konopa, K
Bosquee, L
Marshall, E
Bustin, F
Margerit, S
Fink, C
Stigt, J A
Dingemans, A
Citations
Altmetric:
Abstract
The EORTC 08062 phase II randomised trial investigated the activity and safety of single agent amrubicin, cisplatin combined with amrubicin, and cisplatin combined with etoposide as first line treatment in extensive disease (ED) small cell lung cancer (SCLC).
Description
Date
2011-10
Publisher
Collections
Keywords
Type
Article
Citation
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. 2011, 47 (15):2322-30 Eur J Cancer